MarketFoolery

Will gene therapy companies produce healthy returns for investors? Ron Gross explains why he’s investing in gene therapy companies and shares his big question for the year ahead.

With more people buying more stuff online and more stuff getting shipped, who’s making all those cardboard boxes?  Mike Olsen shares why he’s interested in box-makers like WestRock and International Paper. Plus, we discuss the curious case of consumer goods stocks as Mike makes the case for why “dividends have become quite sexy.”

Will Twitter fly higher in 2018?  Jason Moser tackles that question, explains why he’s bullish on a telehealth company, and talks about what tax reform means for investors.

The holiday season can be a joyous, fun time. It can also be tough for any number of reasons. Chris Hill shares a few thoughts about the sudden loss of a Motley Fool colleague, before handing the show over to the late, great Louis Armstrong.

Bed Bath & Beyond struggles, while Pacific Gas & Electric suspends its dividend in the face of mounting lawsuits. Motley Fool Asset Management’s Bill Barker analyzes the latest on both. Plus, we dip into the Fool Mailbag and shake our heads in amazement as Long Island Iced Tea Corp. pivots to blockchain technology. (Tangents include New Orleans restaurants vs. San Francisco’s, the Ark of the Covenant, and the comedic stylings of Bob Newhart.)